Savolitinib vs. Sunitinib in MET-driven PRCC. (NCT03091192)
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
🩺 Plain-English Summary (8th-Grade Level)
This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.
Who can join: Review the eligibility criteria below.
Location: Research Site — La Jolla, California
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (59 Sites)
Showing the first 25 of 59 sites.
- Research Site — La Jolla, California
- Research Site — Atlanta, Georgia
- Research Site — Chicago, Illinois
- Research Site — Iowa City, Iowa
- Research Site — Boston, Massachusetts
- Research Site — Kansas City, Missouri
- Research Site — New York, New York
- Research Site — Nashville, Tennessee
- Research Site — Barretos,
- Research Site — Curitiba,
- Research Site — Passo Fundo,
- Research Site — Pelotas,
- Research Site — Porto Alegre,
- Research Site — Porto Alegre,
- Research Site — Porto Alegre,
- Research Site — Rio de Janeiro,
- Research Site — São José do Rio Preto,
- Research Site — São Paulo,
- Research Site — São Paulo,
- Research Site — Bordeaux,
- Research Site — Vandœuvre-lès-Nancy,
- Research Site — Villejuif,
- Research Site — Arezzo,
- Research Site — Meldola,
- Research Site — Milan,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment — Orlando, Florida
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib — La Jolla, California
- Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer — St Louis, Missouri
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC — Huntsville, Alabama
- Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy — Fullerton, California
Explore by condition: All Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.